Article Contents ::
- 1 Details About Generic Salt :: Flurazep
- 2 Main Medicine Class:: Sedative and hypnotic,Benzodiazepine
- 3 (flure-AZE-uh-pam HIGH-droe-KLOR-ide) Dalmane, Apo-Flurazepam, Novo-Flupam, PMS-Flurazepam, Somnol, Som Pam Class: Sedative and hypnotic/Benzodiazepine
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Flurazep
Main Medicine Class:: Sedative and hypnotic,Benzodiazepine
(flure-AZE-uh-pam HIGH-droe-KLOR-ide)
Dalmane, Apo-Flurazepam, Novo-Flupam, PMS-Flurazepam, Somnol, Som Pam
Class: Sedative and hypnotic/Benzodiazepine
Drugs Class ::
Action Potentiates action of gamma-aminobutyric acid, an inhibitory neurotransmitter, resulting in increased neural inhibition and CNS depression, especially in limbic system and reticular formation.
Indications for Drugs ::
Indications Treatment of insomnia.
Drug Dose ::
Route/Dosage
ADULTS: PO 15 to 30 mg at bedtime. ELDERLY OR DEBILITATED PATIENTS: PO 15 mg until individual response is determined.
Contraindication ::
Contraindications Hypersensitivity to benzodiazepines; pregnancy.
Drug Precautions ::
Precautions
Pregnancy: Contraindicated. Lactation: Excreted in breast milk. Children: Not recommended in children < 15 yr. Elderly or debilitated patients: Increased side effects; start with lowest dose. Anterograde amnesia: Has occurred with similar drugs. Alcohol may increase risk. Depression: Administer with caution to severely depressed patients or those with suicidal tendencies. Signs and symptoms of depression may be intensified. Renal or hepatic impairment: Use with caution. Abnormal liver function tests and blood dyscrasias have occurred. Withdrawal: Withdrawal symptoms may occur after discontinuation of higher doses taken over long periods.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
CV: Palpitations; chest pains; tachycardia; hypotension (rare). CNS: Dizziness; drowsiness; lightheadedness; staggering; ataxia; falling; lethargy; confusion; impaired memory; headache; weakness; paradoxical excitement; talkativeness; euphoria; apprehension; irritability; hallucinations; slurred speech; depression. DERM: Pruritus; rash. EENT: Difficulty focusing; blurred vision; burning of eyes; taste alterations. GI: Heartburn; nausea and vomiting; diarrhea; constipation; anorexia; upset stomach; GI pain; dry mouth. GU: Urinary incontinence; urinary retention, hesitancy or urgency. HEMA: Leukopenia; granulocytopenia. HEPA: Elevated AST, ALT, bilirubin and alkaline phosphatase; hepatitis. RESP: Shortness of breath. OTHER: Tolerance; physical and psychological dependence; body and joint pains; sweating; flushing.
Drug Mode of Action ::
Action Potentiates action of gamma-aminobutyric acid, an inhibitory neurotransmitter, resulting in increased neural inhibition and CNS depression, especially in limbic system and reticular formation.
Drug Interactions ::
Interactions
Alcohol, other CNS depressants: Additive CNS depressant effects; may continue several days after discontinuation. Cimetidine, disulfiram, oral contraceptives, isoniazid, omeprazole: Increased effects of flurazepam. Digoxin: Serum digoxin concentrations may increase. Phenytoin: Serum concentrations may be increased. Rifampin: Decreased effects of flurazepam. Theophyllines: May antagonize sedative effects.
Drug Assesment ::
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies.
- Perform baseline neuro assessment and reassess with initiation of drug.
- Ensure that side rails are raised after administration.
- Assist patient with ambulation after drug administration.
- Assess vision before beginning drug therapy and monitor during initial treatment period.
- Ensure that baseline CBC, liver and kidney function tests have been obtained before beginning therapy, and monitor at regular intervals.
- Assess for signs of bleeding (eg, petechiae, bruising, oozing at puncture sites).
- Assess for right upper quadrant abdominal tenderness or jaundice.
|
Drug Storage/Management ::
Administration/Storage
- Administer at bedtime with fluid.
- Store at room temperature in light-resistant container.
Drug Notes ::
Patient/Family Education
- Caution patient that this medication must not be taken during pregnancy or when pregnancy is possible. Advise patient to use reliable form of birth control while taking this drug.
- Tell patient to take drug with full glass of water at bedtime.
- Emphasize importance of not exceeding recommended dosage. If symptoms do not improve within 2 to 3 days of beginning drug therapy, or if tolerance develops, notify physician.
- Tell patient not to stop taking drug abruptly to avoid withdrawal symptoms. Explain that nighttime sleep may be disturbed for 1 to 2 nights after gradual discontinuation.
- Instruct patient to monitor weight and to report any excessive gain or loss.
- Advise patient to report the following symptoms to physician: Palpitations or chest pain, signs of bleeding, abdominal pain, jaundice, shortness of breath, rash, confusion, dizziness, nausea or vomiting.
- Instruct patient to take sips of water frequently, suck on ice chips or sugarless hard candy, or chew sugarless gum if dry mouth occurs.
- Advise patient to avoid intake of alcoholic beverages or other CNS depressants.
- Advise patient that drug may cause drowsiness and to use caution while driving or performing other tasks requiring mental alertness.